Prior to founding 7G BioVentures, Dr. Vincent Xiang was a managing director and Head of Global BioVenture at Hillhouse Capital. Prior to that, he was a partner at 6 Dimensions Capital. He has over 20 years of experience in the life sciences industries in the U.S. and China. From 2013 to 2016, Dr. Xiang was Managing Director and Head of international investments & business development at Humanwell Healthcare Group (600079.SH), which has $1.3B/year in revenue in 2015. He led the $550M acquisition of US Epic Pharma, the largest M&A ever done by a Chinese healthcare firm. Prior to that, he worked as Managing Director of Burrill Life Science Venture Capital Fund, scouting first in class assets. From 2004 to 2012, Dr. Xiang was Portfolio Manager/Analyst at Franklin Templeton, investing in global life science companies at all stages. Previously, he was Vice President of business development at Genyous, a US biotech start-up. He was also Director of venture investment at Acacia Research, Associate at BioAdvance (a healthcare Angel fund), and Irvington Fellow at Skirball Center and licensed his patented technology to Millennium Pharmaceutical for royalty payments. Dr. Xiang began his career at Sinopharm in China.

Dr. Xiang received his Ph.D. in molecular biology from University at Stony Brook, MBA from the Wharton School, and B.S. in Immunology and Microbiology from Fudan University. He is a founding member of BayHelix Group, founders and board members of two life science startups.